Status:

RECRUITING

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

Lead Sponsor:

The University of Texas Health Science Center at San Antonio

Conditions:

End Stage Renal Disease

Fatigue

Eligibility:

All Genders

25-74 years

Phase:

PHASE1

PHASE2

Brief Summary

Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of t...

Detailed Description

While taking part in this study, participants will be asked to complete study procedures with the researchers or study staff three times a week during routine dialysis visits. Collections of blood, ur...

Eligibility Criteria

Inclusion

  • Male and female ESKD patients between aged 25-74 yrs on maintenance in-center hemodialysis procedure 3 times/week for ≥3 months with an arteriovenous fistula or graft.
  • Blood hemoglobin of ≥10.0 g/dL based on most recent routine laboratory profile.
  • Dialysis adequacy measured with Kt/V of ≥1.2
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion

  • Currently on bupropion or hypersensitivity/ intolerance to bupropion by history and monoamine oxidase inhibitors.
  • Diagnosis or history of eating disorders (bulimia or anorexia nervosa) and seizure.
  • Pregnant, lactating, childbearing women
  • History of post-acute COVID-19 syndrome
  • Diagnosis of depression and/or on antidepressants and bipolar affective disorder
  • Patient Health Questionnaire (PHQ)-9 score of ≥10
  • Diagnosis of cognitive impairment including dementia
  • Current participation in another interventional trial
  • Scheduled for kidney transplantation in next 6 months
  • Life expectancy \<6 months as judged by the attending nephrologist/primary care physician.
  • Current or history of substance abuse or dependency.

Key Trial Info

Start Date :

February 2 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 30 2027

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT06609343

Start Date

February 2 2026

End Date

January 30 2027

Last Update

December 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Dialysis Medical Center (DMC)

San Antonio, Texas, United States, 78229

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis | DecenTrialz